Long-term Treatment With Golimumab for Severe Uveitis

Ocul Immunol Inflamm. 2014 Apr;22(2):90-5. doi: 10.3109/09273948.2013.844265. Epub 2013 Oct 21.

Abstract

Purpose: To evaluate the long-term efficacy of golimumab in patients with severe recalcitrant uveitis who had inadequate response to previous biologics.

Methods: Retrospective study (13 patients with JIA, 4 with HLA-B27-associated uveitis). Indication for treatment was active uveitis despite biologics. Golimumab dosing was 50 mg monthly/subcutaneously.

Main outcome measures: uveitis activity, visual acuity improvement, reduction of systemic therapy (corticosteroids/immunosuppressants), adverse events.

Results: Of 17 patients (34 affected eyes), response to golimumab was seen in 14 patients; at last visit uveitis was inactive in 12 patients. Three patients were nonresponders. Mean follow-up time on golimumab was 21.9 months. Visual acuity remained stable in 26 eyes, improved in 7, and worsened in 1. Mean systemic prednisolone dose before and after golimumab was 12.5-3.5 mg/day. One patient developed pulmonary infection.

Conclusions: Golimumab may be a promising new therapeutic option for severe uveitis patients who have not responded to other biologics.

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Monoclonal / administration & dosage*
  • Arthritis, Juvenile / complications
  • Arthritis, Juvenile / immunology
  • Autoimmune Diseases
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • HLA-B27 Antigen / immunology
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Uveitis / diagnosis
  • Uveitis / drug therapy*
  • Uveitis / immunology
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • HLA-B27 Antigen
  • Tumor Necrosis Factor-alpha
  • golimumab